logo-loader
AIM:RENE OTC:RNUGF

ReNeuron Group PLC

Receive alerts
Market:
AIM
Price
3.38 GBX
Day Change
-2.17%
Market Cap:
£1.93 m
52 weeks high
11.50
52 weeks low
3.28

In brief

ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, its CustomEX platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects.

ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.

Snapshot

  • ReNeuron shares suspended as urgent cash injection needed
  • ReNeuron Group PLC shares soar on impressive data from latest breakthrough
  • ReNeuron Group’s investment potential ‘remains intact’, 2024 cash runway secured, says Liberum
  • ReNeuron has extended cash runway as it focuses on validating its exosome platform